A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Halfords Group PLC: Holding in Company
DJ Halfords Group PLC: Holding in Company
Halfords Group PLC (HFD)
Halfords Group PLC: Holding in Company
17-Feb-2021 / 16:22 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS HALFORDS GROUP plc
1a. Identity of the issuer or the underlying issuer of existing shares
to which voting rights are attachedii:
1b. Please indicate if the issuer is a non-UK issuer (please mark with an X if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an X )
DJ Eve Sleep plc: Holding in Company Eve Sleep plc (EVE) Eve Sleep plc: Holding in Company 15-Feb-2021 / 16:23 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The
Fusion is a Belfast based biotechnology company providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion s proprietary CDRx
TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;